BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 26519280)

  • 1. Phenotypical Differences in Neuronal Cultures Derived via Reprogramming the Fibroblasts from Patients Carrying Mutations in Parkinsonian Genes LRRK2 and PARK2.
    Konovalova EV; Novosadova EV; Grivennikov IA; Illarioshkin SN
    Bull Exp Biol Med; 2015 Oct; 159(6):772-5. PubMed ID: 26519280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of an induced pluripotent stem cell line (CSC-44) from a Parkinson's disease patient carrying a compound heterozygous mutation (c.823C>T and EX6 del) in the PARK2 gene.
    Marote A; Pomeshchik Y; Goldwurm S; Collin A; Lamas NJ; Pinto L; Salgado AJ; Roybon L
    Stem Cell Res; 2018 Mar; 27():90-94. PubMed ID: 29353703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Derivation, Characterization, and Neural Differentiation of Integration-Free Induced Pluripotent Stem Cell Lines from Parkinson's Disease Patients Carrying SNCA, LRRK2, PARK2, and GBA Mutations.
    Momcilovic O; Sivapatham R; Oron TR; Meyer M; Mooney S; Rao MS; Zeng X
    PLoS One; 2016; 11(5):e0154890. PubMed ID: 27191603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRRK2 Expression Is Deregulated in Fibroblasts and Neurons from Parkinson Patients with Mutations in PINK1.
    Azkona G; López de Maturana R; Del Rio P; Sousa A; Vazquez N; Zubiarrain A; Jimenez-Blasco D; Bolaños JP; Morales B; Auburger G; Arbelo JM; Sánchez-Pernaute R
    Mol Neurobiol; 2018 Jan; 55(1):506-516. PubMed ID: 27975167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. G2019S LRRK2 mutant fibroblasts from Parkinson's disease patients show increased sensitivity to neurotoxin 1-methyl-4-phenylpyridinium dependent of autophagy.
    Yakhine-Diop SM; Bravo-San Pedro JM; Gómez-Sánchez R; Pizarro-Estrella E; Rodríguez-Arribas M; Climent V; Aiastui A; López de Munain A; Fuentes JM; González-Polo RA
    Toxicology; 2014 Oct; 324():1-9. PubMed ID: 25017139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson's Disease-Related LRRK2 G2019S Mutation.
    Schwab AJ; Ebert AD
    Stem Cell Reports; 2015 Dec; 5(6):1039-1052. PubMed ID: 26651604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons.
    López de Maturana R; Lang V; Zubiarrain A; Sousa A; Vázquez N; Gorostidi A; Águila J; López de Munain A; Rodríguez M; Sánchez-Pernaute R
    J Neuroinflammation; 2016 Nov; 13(1):295. PubMed ID: 27863501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of an induced pluripotent stem cell line (CSC-41) from a Parkinson's disease patient carrying a p.G2019S mutation in the LRRK2 gene.
    Marote A; Pomeshchik Y; Collin A; Goldwurm S; Lamas NJ; Pinto L; Salgado AJ; Roybon L
    Stem Cell Res; 2018 Apr; 28():44-47. PubMed ID: 29414418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytogenetic Analysis of the Results of Genome Editing on the Cell Model of Parkinson's Disease.
    Vetchinova AS; Simonova VV; Novosadova EV; Manuilova ES; Nenasheva VV; Tarantul VZ; Grivennikov IA; Khaspekov LG; Illarioshkin SN
    Bull Exp Biol Med; 2018 Jul; 165(3):378-381. PubMed ID: 30006877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction.
    Sanders LH; Laganière J; Cooper O; Mak SK; Vu BJ; Huang YA; Paschon DE; Vangipuram M; Sundararajan R; Urnov FD; Langston JW; Gregory PD; Zhang HS; Greenamyre JT; Isacson O; Schüle B
    Neurobiol Dis; 2014 Feb; 62():381-6. PubMed ID: 24148854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Leucine-rich repeat kinase 2 (LRRK2) and Parkinson protein 2 (parkin, PARK2) genes mutations in Slovak Parkinson disease patients.
    Bognar C; Baldovic M; Benetin J; Kadasi L; Zatkova A
    Gen Physiol Biophys; 2013 Mar; 32(1):55-66. PubMed ID: 23531835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
    Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
    Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of induced pluripotent stem cells (IBMSi011-A) from a patient with Parkinson's disease carrying LRRK2 p.I1371V mutation.
    Lin HI; Cheng YC; Ko HW; Wen CH; Lu HE; Huang CY; Hsieh PCH; Lin CH
    Stem Cell Res; 2019 May; 37():101447. PubMed ID: 31029016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased Sirtuin Deacetylase Activity in LRRK2 G2019S iPSC-Derived Dopaminergic Neurons.
    Schwab AJ; Sison SL; Meade MR; Broniowska KA; Corbett JA; Ebert AD
    Stem Cell Reports; 2017 Dec; 9(6):1839-1852. PubMed ID: 29129681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and clinical features of LRRK2 mutations in patients with Parkinson's disease in southern Spain.
    Gao L; Gómez-Garre P; Díaz-Corrales FJ; Carrillo F; Carballo M; Palomino A; Díaz-Martín J; Mejías R; Vime PJ; López-Barneo J; Mir P
    Eur J Neurol; 2009 Aug; 16(8):957-60. PubMed ID: 19473361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation and characterization of induced pluripotent stem cells from a Parkinson's disease patient carrying the digenic LRRK2 p.G2019S and GBA1 p.N409S mutations.
    Oleksy C; Massart F; Goldwurm S; Arado A; Arena G; Boussaad I; Krüger R
    Stem Cell Res; 2023 Oct; 72():103212. PubMed ID: 37832355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of gene-corrected iPSC line, KIOMi002-A, from Parkinson's disease patient iPSC with LRRK2 G2019S mutation using BAC-based homologous recombination.
    Lee SY; Chung SK
    Stem Cell Res; 2019 Dec; 41():101649. PubMed ID: 31731184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling neurological diseases with induced pluripotent cells reprogrammed from immortalized lymphoblastoid cell lines.
    Fujimori K; Tezuka T; Ishiura H; Mitsui J; Doi K; Yoshimura J; Tada H; Matsumoto T; Isoda M; Hashimoto R; Hattori N; Takahashi T; Morishita S; Tsuji S; Akamatsu W; Okano H
    Mol Brain; 2016 Oct; 9(1):88. PubMed ID: 27716287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deciphering the role of heterozygous mutations in genes associated with parkinsonism.
    Klein C; Lohmann-Hedrich K; Rogaeva E; Schlossmacher MG; Lang AE
    Lancet Neurol; 2007 Jul; 6(7):652-62. PubMed ID: 17582365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.